Background/Aims: The goal of phase I clinical trials for cytotoxic agents is to find the maximum dose with an acceptable risk of severe toxicity. The most common designs for these dose-finding trials use a binary outcome indicating whether a patient had a dose-limiting toxicity. However, a patient may experience multiple toxicities, with each toxicity assigned an ordinal severity score. The binary response is then obtained by dichotomizing a patient's richer set of data. We contribute to the growing literature on new models to exploit this richer toxicity data, with the goal of improving the efficiency in estimating the maximum tolerated dose. Methods: We develop three new, related models that make use of the total number of dose-limiting and low-level toxicities a patient experiences. We use these models to estimate the probability of having at least one dose-limiting toxicity as a function of dose. In a simulation study, we evaluate how often our models select the true maximum tolerated dose, and we compare our models with the continual reassessment method, which uses binary data. Results: Across a variety of simulation settings, we find that our models compare well against the continual reassessment method in terms of selecting the true optimal dose. In particular, one of our models which uses dose-limiting and low-level toxicity counts beats or ties the other models, including the continual reassessment method, in all scenarios except the one in which the true optimal dose is the highest dose available. We also find that our models, when not selecting the true optimal dose, tend to err by picking lower, safer doses, while the continual reassessment method errs more toward toxic doses. Conclusion: Using dose-limiting and low-level toxicity counts, which are easily obtained from data already routinely collected, is a promising way to improve the efficiency in finding the true maximum tolerated dose in phase I trials.
Introduction
Phase I clinical trials are small studies whose aim is to identify the maximum tolerated dose (MTD) of a treatment, that is, the highest dose with an acceptable probability of severe dose-limiting toxicity (DLT). The selected dose is then recommended for additional, larger scale testing in a phase II trial. For cytotoxic agents such as chemotherapy, a key feature of phase I trials is that they measure only toxicity and ignore efficacy. 1 The omission of efficacy data can be justified by assuming that as dose increases, so do the probabilities of both DLT and therapeutic effect. Therefore, the MTD, based solely on toxicity data, is optimal in the sense that increasing the dose beyond it would lead to unacceptable risk of toxicity, while decreasing the dose would decrease the efficacy. Phase I trials typically enroll patients sequentially in small cohorts, adaptively changing what dose to assign to the next cohort. At the end of the trial, one of the pre-specified doses will be selected as the MTD. Two competing methods for implementing this framework are the 3 + 3 design, 2 which uses a rule-based algorithm for escalating the dose toward the MTD, and the continual reassessment method (CRM), [3] [4] [5] [6] which adaptively updates a statistical model of DLT rates for each dose and uses model-based estimates of those rates to select the next dose. Both the 3 + 3 design and the CRM use a binary indicator to ensure whether a patient had a DLT.
While most phase I trials have used binary data, 7, 8 richer data are routinely collected. We refer to the ''full data'' as a vector of event grades for each patient, capturing all events a patient has across multiple event types, for example, infections, gastrointestinal disorders, or hematologic events. Each grade is an integer from 0 to 5, with higher grades indicating greater severity, according to the Common Terminology Criteria for Adverse Events. 9 A DLT is commonly taken to be an event of grade 3 or higher, although this may vary by protocol.
A number of authors have explored using this richer toxicity data in different ways. Bekele and Thall 10 developed a method to incorporate the full data, adopting a multivariate ordinal probit model. The model estimates, for each dose level, the probabilities of observing each grade for every event type. Rather than base their adaptive dose-finding algorithm on DLT rates, Bekele and Thall defined a new metric, the ''total toxicity burden,'' as a sum of weighted event grade probabilities, with weights elicited from physicians and probabilities estimated by the model. The algorithm then seeks a pre-specified target total toxicity burden to define the MTD. The appeal of this approach is that it never dichotomizes the toxicity information, either before modeling or after in selecting the MTD, and it provides a different target than the DLT rate. A drawback, however, is that it is not straightforward to think in the total toxicity burden scale, and thus choosing and explaining the target are challenging.
Yuan et al. 11 developed a quasi-continuous toxicity score to reflect the highest grade event a patient experiences. A quasi-Bernoulli likelihood is used to carry out the estimation and inform dose escalation decisions. This method worked well in simulation studies, but similar to the CRM, it only uses one event per patient. Thus, Chen et al. 12 extended Yuan et al.'s study to the case where patients may have multiple toxicities with varying grades. They used isotonic regression to estimate the average toxicity score at each dose level. Alternative quasi-continuous toxicity scores have been proposed by Ezzalfani et al. 13 and Wang and Ivanova.
14 Lee et al. 15 proposed using multiple constraints on the percentiles of a toxicity score, as opposed to the typical single constraint of the score being less than a threshold. Their multi-constraint framework can work with any of the aforementioned scores. As with Bekele et al., using these methods with novel scores requires redefining the MTD.
Van Meter et al. 16 proposed using the original ordinal adverse event grades (0-5) in a proportional odds model, finding similar performance to the CRM in how often the correct MTD was selected. As with Yuan et al., the response for each patient was a single grade, which could be taken as the maximum grade across all the patient's events.
We propose three new models that make use of phase I data in a way that we have not previously seen in the literature. Specifically, one model requires all of a patient's events to be categorized as DLTs or not, and models the total count of DLTs per patient. Our two other models require that events be categorized as DLTs or low-level toxicities, which we define as events of medical significance but which should not prevent a patient from continuing treatment, and we model the total number of DLTs and low-level toxicities per patient. As a motivation for our model, we note that in a review of 54 singleagent phase I trials, Postel-Vinay et al. 17 found a total of 2084 patients experienced 24,918 adverse events, including 189 patients who experienced 300 DLTs. These numbers imply that, on average, patients experienced 12 events, and that 9% of patients had an average of 1.6 DLTs. Thus, data with multiple events and in particular multiple DLTs per patient are available. Our method uses the same adaptive dose-finding framework as the CRM but incorporates these richer data in an attempt to better estimate the DLT rates.
Data and notation
Let N i be the DLT count and M i the total event count (DLTs and low-level toxicities) for patient i, so the patient experiences a DLT if N i .0. These counts are obtained from the full data, with a clinician categorizing each adverse event as a DLT or low-level toxicity. A patient may experience multiple adverse events, both across and within event types, so in principle N i and M i are unbounded above. With data from n patients, let N + = P n i = 1 N i and M + = P n i = 1 M i . Let X i 2 f1, . . . , J g be the dose level assigned to patient i among J pre-specified levels. We define r + = P n i = 1 r X i as the total scaled dose given to patients. The scaled dose values, r 1 , . . . , r J , will be defined in the next section. A common feature in phase I designs is the need for investigators to specify, a priori, a so-called probability skeleton. This represents the best prior guess for the DLT rate for each candidate dose, which we denote p 0j , j = 1, . . . , J . To ensure that the probability of DLT increases monotonically with dose, we require p 01 \ Á Á Á \p 0J .
Models and methods
In this section, we specify our three models, in increasing order of complexity, and we show how each model is used to estimate DLT rates.
Model 1: using DLT counts
Our first model uses only DLT counts, not low-level toxicity counts. We model the DLT count as an increasing function of dose, N i jb, X i = j;Poisson(br j ), where r j is an increasing function of j that rescales the doses to agree with the skeleton. We will show later how to calculate r j . As with the CRM, our model has only one parameter, b, which we give a Bayesian prior,
According to our model, the probability of a patient having any DLTs at dose j is 
Model 1: likelihood and estimation
The likelihood for data from n patients is
We estimate the DLT rate, specifically the probability of having any DLTs at dose j, denotedp j , as the posterior mean of
Àã b . Thus, we have a closed-form Bayesian estimator for DLT rates, and no numerical integration or Markov chain Monte Carlo is necessary.
Model 2: using DLT and low-level toxicity counts Our second model incorporates more information than model 1. First, we use a Poisson distribution to model a patient's total event count M i , such that M i ju, X i = j;Poisson(ur j ), u.0, where again r j rescales the dose to agree with the skeleton. Note that we reuse the symbol r j to emphasize the similarity with model 1, but the calculation of r j is separate for the two models.
Next, conditional on M i , the number of DLTs N i is given a binomial distribution, N i jq, M i , X i ;Binomial (M i , q). The parameter q is the probability that a given event is a DLT rather than a low-level toxicity. Note that, although we condition on dose X i , we do not include them on the right-hand side. Thus, we are assuming that the proportion of DLTs is constant across doses; we will relax this assumption in model 3. We assume that u and q are a priori independent with marginal priors u;Gamma(s The modeled probability of a patient having any DLTs at dose j is
Thus, we calculate r j by solving the equation
where 2 F 1 is the Gaussian hypergeometric function, 18 and p( Á ) denotes a density. This equation can be solved numerically for r j , for any choice of skeleton p 0j and hyperparameters s u , a q , and b q .
Model 2: likelihood and estimation
With data for n patients, the full likelihood is
Due to the separability of the likelihood and the prior independence of the parameters, we can estimate u separately from q. Using a gamma prior for u, we have ujData;Gamma(ã u ,b u ), whereã u = s
For q, using a beta prior gives us qjData;Beta(ã q ,b q ), whereã q = a q + N + and
Finally, we estimate the posterior DLT rate at dose
In the R programming language, 19 the function 2 F 1 is available in the gsl package 20 under the name hyperg_2F1.
Model 3: using DLT and low-level toxicity counts, version 2
Our third model is very similar to model 2. The key difference is that q, the probability of an event being a DLT rather than a low-level toxicity, is assumed to vary with dose. Specifically, we model q = q j (a) = expit(À 3 + e a r j ). The requirement that the coefficient of r j is positive ensures that the log-odds of an event being a DLT increases with increasing dose level j. We now place a prior on a instead of q: a;Normal(a 0 , s 2 a ). According to model 3, the probability of a patient having any DLTs at dose j is p j (u, a) = 1 À e Àuq j (a)r j . The rescaled doses r j are found by numerically solving
u , where the last expectation is with respect to the distribution of a only.
Model 3: likelihood and estimation
The likelihood factors into separate functions of the two parameters,
Due to the separability of the likelihood and the prior independence of the parameters, we can estimate u separately from a. The posterior for u is the same as in model 2: ujData;Gamma(ã u ,b u ), wherẽ
For a, however, a closed-form posterior is not available. To obtain the posterior, we use a simple discrete grid-based approximation, which is computationally efficient for a single parameter. 21 Finally, we estimate the posterior DLT rate at dose j
Àã u jData, where the final expectation is with respect to the posterior distribution of a.
Dose-finding algorithm
As a trial is run, patients are enrolled sequentially, and with data from each new patient, we update our estimates of the DLT rates. We use the following algorithm to estimate the MTD. First, we choose a set of J dose levels, and we set a target DLT rate t, denoting the maximum acceptable probability of a patient having any DLTs. We enroll the first patient at the lowest dose, level 1, and follow the patient for a desired time. Using the patient's data and one of our models, we estimate the DLT ratesp 1 , . . . ,p J . Our updated estimate of the MTD, denoted d MTD, is the dose j that minimizes jp j À tj. The next patient is then assigned either to d MTD or to the lowest dose not yet assigned, whichever is smaller. This rule prevents the sequence of dose assignments from skipping over untested dose levels. We continue to enroll new patients and update d MTD using all the patients' data. Once we have observed a desired number of patients, the trial concludes and we obtain a final estimate of the MTD.
Simulation study and comparison with CRM
We simulate adaptive trials using each of our proposed models, and we record how often the true MTD is selected. We include a comparison with a CRM model, described in the next section.
CRM model for comparison
We will use a CRM model that is related to all of our proposed models. Specifically, let Y i = I(N i .0) be a binary indicator of whether patient i had a DLT. Recall that, according to our three models, the probability of DLT is, respectively,
Àuqr j , and p j (u, a) = 1 À e Àuq j (a)r j . For the CRM, with a single parameter f, we have to specify a model for Pr (
Àfr j , f.0, due to its functional similarity to our models, which will facilitate jointly calibrating the hyperparameters of each model. Our prior on f is f;Gamma(s 
Simulating a patient's toxicity data
In our simulation study, for the data-generating mechanism, we assume that there are K = 15 distinct event types, each of which can experience no event, a low-level toxicity, or a DLT, and there is a patientspecific frailty influencing the probabilities of those outcomes. The observed data for a patient are the total number of DLTs and low-level toxicities across the K event types. We chose to use K = 15 as a middle ground among the number of event types we have seen in published trials; 10, 17, 22 however, we will also conduct a small sensitivity analysis with K = 7.
Letting Y ik 2 f0 = no event, 1 = low À level toxicity, 2 = DLTg be the response for patient i in event type k = 1, . . . , K, we use a cumulative logit model, logit Pr (Y ik ! yjX i ) = h iy = a y + g i + r X i for y = 1, 2, where g i ;Normal(0, g 2 sd ) is a random patientspecific frailty, X i is the dose, and r X i rescales the dose to obtain a desired probability of DLT. The multinomial probabilities p iy = Pr (Y ik = yjX i ) implied by this model are
, and p i2 = expit(h i2 ). Note that the linear predictor h iy does not depend on the event type k, that is, for simplicity we make all event types have the same multinomial probabilities.
The number of DLTs for patient i is
Simulation scenarios
Using our data-generating mechanism and dose-finding algorithm, we can simulate full trials. In each simulated trial, there are J = 5 candidate dose levels, we will enroll n patients one at a time, and the target DLT rate is t = 30%. We use a skeleton of (10%, 20%, 30%, 40%, 50%). We must also specify some model-specific tuning parameters: for model 1, we use s b = 1. For model 2, we use s u = 0:8, a q = 2, and b q = 8. For model 3, we use s u = 0:8, a 0 = 0:8, and s a = 0:7. For the CRM model, we use s f = 1. These hyperparameter values were chosen so that the prior DLT rate distributions at each dose are close across the four models, as shown in Figure 1 .
We consider a variety of scenarios by varying three factors: (1) the sample size n, with either 30 or 60 patients; (2) the true DLT rates for all J doses, thereby determining which dose is the true MTD; and (3) the parameters for our simulation model, a 1 and g sd . All scenarios use K = 15 event types. For the scenarios, we call s-A, s = 1, . . . , J , we set a 1 = 2 and g sd = 0:5. For scenarios s-B, we set a 1 = 2:5 and g sd = 0:75. The relevance of these parameters is that, in the A scenarios, the simulated event counts M i are typically small, while in the B scenarios, M i is more likely to reach its upper bound of 15 (i.e. there is an event in all 15 event types).
Thus, the B scenarios present more of a challenge for our models 1, 2, and 3, which have no concept of an upper bound for the event count. For example, in scenario 3-A, with true DLT rates (10%, 20%, 30%, 40%, 50%), the probabilities of a patient having at least 10 events at the different doses are (0%, 0:004%, 0:06%, 0:33%, 1:2%). In contrast, for scenario 3-B, with the same DLT rates, the probabilities of having at least 10 events are (0:02%, 0:38%, 1:8%, 4:9%, 11%). Table 1 shows the true DLT rates for each scenario. Note that in scenarios s-A and s-B, the true MTD is dose s.
Simulation results
For each simulation scenario and statistical model, we simulated 10,000 adaptive trials. The results are reported in Tables 2 and 3, for 30 and 60 patients, respectively, with the following summary statistics: the percentage of trials in which each dose is selected as the MTD, the average number of patients (out of 30 or 60) assigned to each dose during a trial, and a score that measures how far the true DLT rate of the selected MTD is from the target t. We actually consider two The bold entries highlight the maximum tolerated dose in each scenario. scores, defined as score k = P J j = 1ŝ j loss k (p j , t), whereŝ j is the percentage of trials in which dose j is selected as the MTD, p j is the true DLT rate at dose j, loss 1 (p, t) = jp À tj, and loss 2 (p, t) = jp À tjI(p t) + 2jp À tjI(p.t). Note that loss 2 implies a higher penalty than loss 1 for picking dose levels above the target rather than below. For both scores, smaller values are better, and a score of 0 is ideal. In Table 2 , we see that, in the A scenarios, our models consistently do at least as well and often better than the CRM, picking the correct MTD more often and treating more patients at the correct MTD. In the B scenarios, the results are more mixed. For scenarios 2-B through 4-B, our models typically do around as well as the CRM in selecting the correct MTD. However, when not picking the correct MTD, our models have a clear tendency to select doses lower than the MTD, while the CRM appears more likely to pick higher doses. This is reflected in the Score 2 column, where our models consistently have lower scores. This trend is more pronounced in scenarios 1-B and 5-B, where the true MTD is the lowest or highest dose, respectively. In scenario 1-B, our models do much better than the CRM, but this is likely because our models prefer lower doses. Similarly, in scenario 5-B, the CRM does considerably better, but this is likely because the CRM prefers higher doses. It is difficult to identify a clear winner among the models across all scenarios. If we ignore scenario 5-B, then model 3, which incorporates low-level toxicities and allows the probability of DLT versus low-level toxicity to vary with dose, is the preferred model. This validates the idea that counting events and using low-level toxicities can improve estimation of the MTD. However, model 3 is clearly not preferred in scenario 5-B, in which the highest dose is the MTD and patients commonly experience many events, sometimes reaching the maximum of 15 events. We consider this scenario somewhat unlikely, however, as a welldesigned trial will typically have the true MTD among the middle dose levels.
Example trial
We illustrate the behavior of model 3 by presenting a full simulated trial. We simulated the trial data using scenario 4-A described previously, where the true DLT rates are (7%, 14%, 21%, 30%, 40%). The target DLT rate is 30%, so that dose 4 is the true MTD. Our skeleton is (10%, 20%, 30%, 40%, 50%), implying that a priori the MTD is believed to be dose 3. The results from simulating 30 patients are shown in Table  4 . First we note that, looking at the last row of the table, the trial correctly concludes that dose 4 is the MTD. Indeed, although there is still some movement, the trial has mostly fixed on dose 4 by patient 12. Based on the results in Table 2 , model 3 will pick the correct dose in scenario 4-A 53.1% of the time, so this Table 4 . Example of a single simulated trial of 30 patients and five dose levels, using model 3 and scenario 4-A. example trial is in line with expectations. We also note that only one patient has multiple DLTs in this trial, although 18 patients have more than one total event, so our model does have data to facilitate parameter estimation. At the end of the trial, beyond selecting the correct MTD, we have also estimated the DLT rates well: (7%, 12%, 18%, 27%, 38%).
Sensitivity analysis
We conduct a small sensitivity analysis, investigating how model performance varies with changing model parameters and with the number of event types K. In particular, starting from the 2-A scenario, we consider the following three variations: ''Larger variance,'' in which we increase the prior variances of model parameters (s b = 1:4 for model 1; s u = 1:15, a q = 1, and b q = 4 for model 2; s u = 1:3, a 0 = 2, and s a = 1:1 for model 3; and s f = 1:4 for the CRM); ''Smaller variance,'' in which we decrease the prior variances of model parameters (s b = 0:7 for model 1; s u = 0:56, a q = 4, and b q = 16 for model 2; s u = 0:65, a 0 = 3, and s a = 0:8 for model 3; and s f = 0:7 for the CRM); and ''K = 7 event types,'' in which we reduce the number of event types from 15 to 7. We simulated 10,000 adaptive trials of 30 patients with each model and for each described variation. Results are in Table 5 , and we observe that all models are sensitive to the prior variances of model parameters, with the ''smaller variance'' models outperforming the ''larger variance'' models by about 10% in terms of selecting the correct MTD. In contrast, reducing the number of event types made minimal difference compared to the 2-A scenario results in Table 2 . These results suggest that the models, including the CRM, should be carefully calibrated given a variety of plausible DLT rates, while the precise number of event types is less important.
Model properties
To better understand the performance of our models, we investigate the bias in estimating DLT rates with each model. We simulate non-adaptive trials of 10 or 20 patients all receiving the same dose level, and we consider all combinations of true DLT rate and prior guess from 0% to 70% in increments of 2.5%. Patient responses are simulated using A and B scenarios described previously. Figure 2 shows the bias for both the CRM model and our models 1, 2, and 3. In each plot, along the diagonal from bottom left to top right, the true DLT rate and prior guess agree, so we would expect minimal bias near this region. Above the diagonal, the prior guess exceeds the truth, so we would expect positive bias, and vice versa below the diagonal. In Table 2 , we note that our models tend to choose doses below the true MTD more often than the CRM. As a plausible explanation, we see in Figure 2 that our models tend to be more positively biased than the CRM (particularly models 2 and 3). That is, our models overestimate the DLT rates more than the CRM, and thus, the dose selection algorithm picks lower doses. However, large differences between the truth and the skeleton tend to lead to greater bias for the CRM than for our models.
We note that models 2 and 3 tend to select the true MTD less often in the B scenarios than in the A scenarios. This is likely due to a difference between the datagenerating model and models 2 and 3. Specifically, the data-generating model creates low-level toxicity and DLT event counts for a patient, and the sum of these two counts cannot exceed 15, thereby making the two counts negatively correlated. However, models 2 and 3 implicitly force this correlation to be zero. In the A scenarios, both counts are usually low, so they do not influence each other much, and there is minimal conflict with our models. The B scenarios, in contrast, generate higher event counts for a patient, leading to stronger correlations and greater conflict with our models. If we increase the number of event types to K = 60 in our generative model, so that the upper bound is almost never realized in scenarios A and B, then the differences in dose selection percentages between scenarios A and B decrease, although using 60 event types would not be realistic.
In addition, we note that the DLT count N i either explicitly, as in model 1, or implicitly, as in models 2 and 3 after marginalizing over M i , follows a Poisson distribution in our proposed analysis models, while in the data-generating model, N i is binomial. This discrepancy impacts the performance of our models, yet it has no effect on the CRM, which does not attempt to model event counts. For this reason, the CRM should perform exactly the same in scenarios A and B, within Monte Carlo simulation error.
Discussion
Models 1, 2, and 3 all make use of phase I trial data that are routinely collected but rarely analyzed or incorporated into the dose selection algorithm. Model 1 Figure 2 . Bias in estimating DLT rates for CRM model and models 1, 2, and 3. Each pixel in each plot is based on 10,000 simulated trials under scenarios A and B of either 10 or 20 patients. In a trial, all patients receive the same dose level, that is, the trial is not adaptive, and the true DLTrate is the same. The purpose of this figure is to show, for every combination of true DLT rate and prior guess (i.e. skeleton), how well the models do in estimating the DLT rate. DLT: dose-limiting toxicity; CRM: continual reassessment method. makes fewer assumptions than models 2 and 3, placing a Poisson distribution on the number of DLTs, but disregarding the number of low-level toxicities. Models 2 and 3 jointly model a patient's DLT and low-level toxicity counts.
All three models perform comparably to, and sometimes better than, the CRM across a variety of scenarios in our simulation study. Nonetheless, the simulations did suggest that including total number of toxicities and DLTs might lead to conservative dose decisions when the true MTD is at the highest dose. However, we do observe better operating characteristics for some of our models when the MTD is one of the lower doses.
The data-generating model in our simulations was designed both to be biologically plausible and to disagree with our three proposed models, thereby creating fair test scenarios. Although we believe our models generally compare favorably with the CRM, in scenario 5-B, models 2 and 3 perform poorly relative to both the CRM and model 1. The import of this differential depends on how plausible one believes scenario 5-B to be. If the true MTD is rarely the highest dose under consideration, then model 3 clearly bests both the CRM and our models 1 and 2. This suggests that we are indeed gaining useful information and efficiency by modeling event counts and incorporating low-level toxicities.
Models 1-3 tended to slightly overestimate DLT rates in simulations, likely because these models do not put an upper limit on the number of events a patient may have, while the data-generating model does. It may be possible to compensate for some of this bias by specifying a probability skeleton lower than one believes a priori, perhaps by raising the skeleton to a power slightly greater than one. The precise power to use can be chosen via simulation.
In a real trial, it may be desirable to enroll a new patient before the previous patients have finished follow-up. Our models can be extended to handle partial follow-up by scaling the expected number of toxicities in accordance with follow-up, in a manner similar to the time-to-event CRM. 23 Further research is needed to recommend appropriate scaling weights.
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